FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans-Peter Sinn

Research Profile

Disorders

Living Beings

Rats

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
Maria Shahmoradgoli; Hans-Peter Sinn; Özgür Sahin; Otto Mannherz; Yasser Riazalhosseini; Andreas Schneeweiss; Natalia Becker; Daniel Haag; Stefanie Heck; Volker Hovestadt; Peter Lichter
Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer.
Julia Aigner; Holger Hof; Andreas Schneeweiss; Hans-Peter Sinn; Katharina Smetanay; Christof Sohn; Frederik Marmé
Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations.
Marta Faryna; Sebastian Aulmann; Justo Lorenzo Bermejo; Markus Brugger; Rainer Claus; Sven Diederichs; Carolin Konermann; Christoph Plass; Michael Rehli; Joachim Rom; Peter Schirmacher; Hans-Peter Sinn; Dieter Weichenhan; Clarissa Gerhauser
Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans-Peter Sinn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maria Shahmoradgoli; Hans-Peter Sinn; Özgür Sahin; Otto Mannherz; Yasser Riazalhosseini; Andreas Schneeweiss; Natalia Becker; Daniel Haag; Stefanie Heck; Volker Hovestadt; Peter Lichter
Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer.
International journal of cancer. Journal international du cancer 2013;132(11):2714-9.
2013: Julia Aigner; Holger Hof; Andreas Schneeweiss; Hans-Peter Sinn; Katharina Smetanay; Christof Sohn; Frederik Marmé
Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations.
Annals of surgical oncology 2013;20(5):1538-44.
2012: Marta Faryna; Sebastian Aulmann; Justo Lorenzo Bermejo; Markus Brugger; Rainer Claus; Sven Diederichs; Carolin Konermann; Christoph Plass; Michael Rehli; Joachim Rom; Peter Schirmacher; Hans-Peter Sinn; Dieter Weichenhan; Clarissa Gerhauser
Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012;26(12):4937-50.
2012: Michelle G Rath; Christoph Domschke; Joerg Heil; Frederik Marme; Alexander Scharf; Andreas Schneeweiss; Sven Schneider; Hans-Peter Sinn; Christof Sohn; Zdravka Topic; Joachim Rom
Predictors of resectability in breast-conserving therapy.
Archives of gynecology and obstetrics 2012;286(4):1023-31.
2012: M Hahn; S Kluge; Ute Krainick-Strobel; E Krapfl; U Peisker; Hans-Peter Sinn; T Toellner; Diethelm Wallwiener; F Degenhardt; V Duda; J Gissler; Ines Gruber
Interdisciplinary consensus recommendations for the use of vacuum-assisted breast biopsy under sonographic guidance: first update 2012.
Ultraschall in der Medizin (Stuttgart, Germany : 1980) 2012;33(4):366-71.
2011: Christoph Domschke; Florian Schuetz; Yingzi Ge; Joachim Rom; Markus Zorn; Hans-Peter Sinn; Frederik Marmé; Sarah Schott; Joerg Heil; Alexander Scharf; Christof Sohn; Andreas Schneeweiss; Philipp Beckhove
Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients.
Cancer immunology, immunotherapy : CII 2011;60(3):401-11.
2011: Andreas Schneeweiss; F Marmé; Amparo Ruiz; A G Manikhas; A Bottini; M Wolf; Hans-Peter Sinn; Kambiz Mansouri; L Kennedy; Thomas Bauknecht
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(3):609-17.
2009: Christoph Domschke; Florian Schuetz; Yingzi Ge; Tobias Seibel; Christine Falk; Benedikt Brors; Israel Vlodavsky; Nora Sommerfeldt; Hans-Peter Sinn; Marie-Christine Kühnle; Andreas Schneeweiss; Alexander Scharf; Christof Sohn; Volker Schirrmacher; Gerhard Moldenhauer; Frank Momburg; Philipp Beckhove
Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis.
Cancer research 2009;69(21):8420-8.
2009: Tom M Ganten; Jaromir Sykora; Ronald Koschny; Emanuela Batke; Sebastian Aulmann; Ulrich Mansmann; Wolfgang Stremmel; Hans-Peter Sinn; Henning Walczak
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
Journal of molecular medicine (Berlin, Germany) 2009;87(10):995-1007.
2009: Stefanie Heck; Joachim Rom; Verena Thewes; Natalia Becker; Beatrix Blume; Hans-Peter Sinn; Ulrich Deuschle; Christof Sohn; Andreas Schneeweiss; Peter Lichter
Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma.
Cancer research 2009;69(12):5186-93.
2009: Michael H R Eichbaum; Luise M E Weiss; Thomas Bruckner; Andreas Schneeweiss; Hans-Peter Sinn; Gerhard Gebauer; Nikos Fersis; Julia Kussmaul; Christof Sohn
Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
Medical science monitor : international medical journal of experimental and clinical research 2009;15(4):CR156-63.
2009: Hans-Peter Sinn
Breast cancer precursors: lessons learned from molecular genetics.
Journal of molecular medicine (Berlin, Germany) 2009;87(2):113-5.
2008: Hans-Peter Sinn; M Andrulis; Carolin Mogler; Peter Schirmacher
[Virtual microscopy in pathology teaching and postgraduate training (continuing education)].
Der Pathologe 2008;29 Suppl 2():255-8.
2008: Sebastian Aulmann; Z Elsawaf; Roland Penzel; Peter Schirmacher; Hans-Peter Sinn
[Clonal association of flat epithelial atypia and tubular breast cancer].
Der Pathologe 2008;29 Suppl 2():353-6.
2008: Joachim Rom; Gunter von Minckwitz; W Eiermann; M Sievert; B Schlehe; F Marmé; Florian Schuetz; Alexander Scharf; Michael H R Eichbaum; Hans-Peter Sinn; Manfred Kaufmann; Christof Sohn; Andreas Schneeweiss
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(10):1698-705.
2008: Sebastian Aulmann; J Schleibaum; Roland Penzel; Peter Schirmacher; Gerhard Gebauer; Hans-Peter Sinn
Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status.
Journal of clinical pathology 2008;61(9):1034-7.
2008: Stefan Pfister; Stephen Rea; Mikko Taipale; Frank Mendrzyk; Beate Straub; Carina Ittrich; Olaf Thuerigen; Hans-Peter Sinn; Asifa Akhtar; Peter Lichter
The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma.
International journal of cancer. Journal international du cancer 2008;122(6):1207-13.
2008: Sebastian Aulmann; Roland Penzel; Thomas Longerich; Benjamin Funke; Peter Schirmacher; Hans-Peter Sinn
Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer.
Breast cancer research and treatment 2008;107(3):331-5.
2008: Gunter von Minckwitz; Hans-Peter Sinn; Günter Raab; Sibylle Loibl; Jens-Uwe Blohmer; Holger Eidtmann; Jörn Hilfrich; Elisabeth Merkle; Christian Jackisch; Serban D Costa; Angelika Caputo; Manfred Kaufmann
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
Breast cancer research : BCR 2008;10(2):R30.
2007: Klaus Wasser; SK Klein; H Junkermann; Hans-Peter Sinn; S Darai; Wolfgang Neff; Hans-Ulrich Kauczor; Stefan Delorme
[Neoadjuvant chemotherapy of breast carcinomas: what post-therapeutic (preoperative) information is provided by quantitative dynamic MRI?].
Der Radiologe 2007;47(5):421-9.
2007: Andreas Schneeweiss; Ilka Lauschner; Amparo Ruiz; Angel Guerrero; Pedro Sánchez-Rovira; Miguel Angel Seguí; Kay Goerke; Michael Wolf; Alexeyg G Manikhas; Juergen Wacker; Frederik Marmé; Peter Lichter; Hans-Peter Sinn; Christof Sohn; Kambiz Mansouri; Thomas Bauknecht; Meinhard Hahn
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Clinical breast cancer 2007;7(7):555-8.
2007: Ute Rupp; Eva Schoendorf-Holland; Michael H R Eichbaum; Florian Schuetz; Ilka Lauschner; Peter Schmidt; Alexander Staab; Gertraud Hanft; Jens Huober; Hans-Peter Sinn; Christof Sohn; Andreas Schneeweiss
Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
Anti-cancer drugs 2007;18(4):477-85.
2006: Hans-Peter Sinn; Birgit Helmchen; Sebastian Aulmann
[Concepts and problems of lobular neoplasia].
Der Pathologe 2006;27(5):373-80.
2006: Olaf Thuerigen; Andreas Schneeweiss; Grischa Toedt; Patrick Warnat; Meinhard Hahn; Heidi Kramer; Benedikt Brors; Christian Rudlowski; Axel Benner; Florian Schuetz; Björn Tews; Roland Eils; Hans-Peter Sinn; Christof Sohn; Peter Lichter
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1839-45.
2006: Sebastian Aulmann; N Adler; Joachim Rom; Birgit Helmchen; Peter Schirmacher; Hans-Peter Sinn
c-myc amplifications in primary breast carcinomas and their local recurrences.
Journal of clinical pathology 2006;59(4):424-8.
2006: Joachim Rom; Sebastian Aulmann; Andreas Schneeweiss; Christof Sohn; Hans-Peter Sinn
Comparison of immunohistological parameters in primary breast cancers and corresponding locoregional recurrences.
Pathology, research and practice 2006;202(3):125-30.
2005: Andreas Schneeweiss; Florian Schuetz; Christian Rudlowski; Meinhard Hahn; Ilka Lauschner; Hans-Peter Sinn; Dietrich Von Fournier; Christof Sohn
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Anti-cancer drugs 2005;16(9):1023-8.
2005: Michael K Bohlmann; Thomas Rabe; Hans-Peter Sinn; Thomas Strowitzki; Michael Von Wolff
Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2005;21(3):138-41.
2005: Sibylle Loibl; Cornelia Strank; Gunter von Minckwitz; Hans-Peter Sinn; A Buck; Christine Solbach; Klaus Strebhardt; Manfred Kaufmann
Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer.
Breast (Edinburgh, Scotland) 2005;14(3):230-5.
2005: Sebastian Aulmann; Philipp A Schnabel; Birgit Helmchen; Hendrik Dienemann; Peter Drings; Herwart F Otto; Hans-Peter Sinn
Immunohistochemical and cytogenetic characterization of acantholytic squamous cell carcinoma of the breast.
Virchows Archiv : an international journal of pathology 2005;446(3):305-9.
2005: Michelle Nessling; Karsten Richter; Carsten Schwaenen; Peter Roerig; Gunnar Wrobel; Swen Wessendorf; Björn Fritz; Martin Bentz; Hans-Peter Sinn; Bernhard Radlwimmer; Peter Lichter
Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue.
Cancer research 2005;65(2):439-47.
2005: Sibylle Loibl; Angela Buck; Cornelia Strank; Gunter von Minckwitz; Marc Roller; Hans-Peter Sinn; Valérie B Schini-Kerth; Christine Solbach; Klaus Strebhardt; Manfred Kaufmann
The role of early expression of inducible nitric oxide synthase in human breast cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(2):265-71.
2004: Helge Amthor; Thomas Egelhof; Iain McKinnell; Mark E Ladd; Isabelle Janssen; Johannes Weber; Hans-Peter Sinn; Hans-Hermann Schrenk; Michael Forsting; Thomas Voit; Volker Straub
Albumin targeting of damaged muscle fibres in the mdx mouse can be monitored by MRI.
Neuromuscular disorders : NMD 2004;14(12):791-6.
2004: Torsten Mattfeldt; Hans A Kestler; Hans-Peter Sinn
Prediction of the axillary lymph node status in mammary cancer on the basis of clinicopathological data and flow cytometry.
Medical & biological engineering & computing 2004;42(6):733-9.
2004: Andreas Schneeweiss; Ingo J Diel; Manfred Hensel; S Kaul; Hans-Peter Sinn; Kristina Unnebrink; Christian Rudlowski; Ilka Lauschner; Florian Schuetz; Gerlinde Egerer; Rainer Haas; Anthony Ho; Gunther Bastert
Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(11):1627-32.
2004: Andreas Schneeweiss; Jens Huober; Hans-Peter Sinn; Dietrich Von Fournier; Christian Rudlowski; Frank Beldermann; K Krauss; Erich Solomayer; R Hamerla; Diethelm Wallwiener; Gunther Bastert
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
European journal of cancer (Oxford, England : 1990) 2004;40(16):2432-8.
2004: Christoph Fiehn; Ulf Müller-Ladner; Steffen Gay; Stefan Krienke; S Freudenberg-Konrad; Jürgen Funk; A D Ho; Hans-Peter Sinn; Andreas Wunder
Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX.
Rheumatology (Oxford, England) 2004;43(9):1097-105.
2004: Andreas Schneeweiss; Julia Katretchko; Hans-Peter Sinn; Kristina Unnebrink; Christian Rudlowski; Matthias Geberth; Frank Beldermann; Gunther Bastert; Hans-Joachim Strittmatter
Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy.
Anti-cancer drugs 2004;15(2):127-35.
2004: Xuan Liu; Hans-Peter Sinn; Hans Ulrich Ulmer; Rodney J Scott; Ute Hamann
Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.
Hereditary cancer in clinical practice 2004;2(3):139-45.
2003: Susanne Weber-Mangal; Hans-Peter Sinn; Susanne Popp; Rüdiger Klaes; Robert Emig; Martin Bentz; Ulrich Mansmann; Gunther Bastert; Claus R Bartram; Anna Jauch
Breast cancer in young women (< or = 35 years): Genomic aberrations detected by comparative genomic hybridization.
International journal of cancer. Journal international du cancer 2003;107(4):583-92.
2003: Andreas Schneeweiss; Hans-Peter Sinn; Volker Ehemann; Tanja Khbeis; Kai Neben; Ulf Krause; Anthony Ho; Gunther Bastert; Alwin Krämer
Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression.
International journal of cancer. Journal international du cancer 2003;107(3):346-52.
2003: Sebastian Aulmann; Hendrik Bläker; Roland Penzel; Ralf J Rieker; Herwart F Otto; Hans-Peter Sinn
CTCF gene mutations in invasive ductal breast cancer.
Breast cancer research and treatment 2003;80(3):347-52.
2003: Manfred Kaufmann; Gunter von Minckwitz; Roy Smith; Vicente Valero; Luca Gianni; Wolfgang Eiermann; Anthony Howell; Serban-Dan Costa; Philippe Beuzeboc; Michael Untch; Jens-Uwe Blohmer; Hans-Peter Sinn; Rolf Sittek; Rainer Souchon; Augustinus-Harjanto Tulusan; Tanja Volm; Hans-Jörg Senn
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2600-8.
2003: Philipp Beckhove; Florian Schütz; Ingo J Diel; Erich Solomayer; Gunther Bastert; Joanna Foerster; Markus Feuerer; Lianhua Bai; Hans-Peter Sinn; Viktor Umansky; Volker Schirrmacher
Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice.
International journal of cancer. Journal international du cancer 2003;105(4):444-53.
2003: Ute Hamann; Xuan Liu; Nikola Bungardt; Hans Ulrich Ulmer; Gunther Bastert; Hans-Peter Sinn
Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
European journal of human genetics : EJHG 2003;11(6):464-7.
2003: Klaus Wasser; Hans-Peter Sinn; Christian Fink; SK Klein; H Junkermann; H P Lüdemann; Ivan Zuna; Stefan Delorme
Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy.
European radiology 2003;13(6):1213-23.
2003: Andreas Wunder; Ulf Müller-Ladner; Ernst H K Stelzer; Jürgen Funk; Elena Neumann; Gerd Stehle; Thomas Pap; Hans-Peter Sinn; Steffen Gay; Christoph Fiehn
Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(9):4793-801.
2003: Klaus Wasser; SK Klein; Christian Fink; H Junkermann; Hans-Peter Sinn; Ivan Zuna; Michael V Knopp; Stefan Delorme
Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution.
European radiology 2003;13(1):80-7.
2002: N Eschen; Ulrike Bauder-Wüst; Eva Frei; Hans-Hermann Schrenk; Hans-Peter Sinn; Paul Kremer; I Kiprianova; Gernot Hartung
Aminopterin-human serum albumin conjugate (AP-HSA): uptake and cytotoxic effects in tumor cell lines.
International journal of clinical pharmacology and therapeutics 2002;40(12):564-6.
2002: Sibylle Loibl; Gunter von Minckwitz; Sonja Weber; Hans-Peter Sinn; Valérie B Schini-Kerth; Irina Lobysheva; Françoise Nepveu; Georg Wolf; Klaus Strebhardt; Manfred Kaufmann
Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy.
Cancer 2002;95(6):1191-8.
2002: Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Solomayer; Rainer Haas; Gunther Bastert; Anthony Ho
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.
International journal of cancer. Journal international du cancer 2002;100(3):290-6.
2002: Paul Kremer; Gernot Hartung; Ulrike Bauder-Wüst; Hans-Hermann Schrenk; Andreas Wunder; Stefan Heckl; Uwe Zillmann; Hans-Peter Sinn
Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats.
Anti-cancer drugs 2002;13(6):615-23.
2002: Sebastian Aulmann; Martin Bentz; Hans-Peter Sinn
C-myc oncogene amplification in ductal carcinoma in situ of the breast.
Breast cancer research and treatment 2002;74(1):25-31.
2002: Michael V Knopp; N Himmelhan; J Radeleff; H Junkermann; T Hess; Hans-Peter Sinn; Gunnar Brix
[Comparison of methods for quantifying contrast enhancement exemplified by dynamic MRI mammography].
Der Radiologe 2002;42(4):280-90.
2002: Fabian Kiessling; Christian Fink; M Hansen; Michael Bock; Hans-Peter Sinn; Hans-Hermann Schrenk; Martin Krix; Thomas Egelhof; Norbert E Fusenig; Stefan Delorme
Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity.
Investigative radiology 2002;37(4):193-8.
2002: Martin Volkmann; Hans-Peter Sinn; Dirk Gaugel; Manfred Frey; Yaser Hajjar; Jochen Ludwig; Susanne Hänsel; Gunther Bastert; Diethelm Wallwiener; Walter Fiehn; Hanswalter Zentgraf; Jens Huober
Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression.
Oncology 2002;63(3):297-305.
2002: Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Martin Kornacker; Erich Solomayer; Rainer Haas; Gunther Bastert; Anthony Ho
Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
Stem cells (Dayton, Ohio) 2002;20(1):32-40.
2001: Peter E Huber; Jürgen W Jenne; Ralf Rastert; I Simiantonakis; Hans-Peter Sinn; Hans-Joachim Strittmatter; Dietrich Von Fournier; M F Wannenmacher; Jürgen Debus
A new noninvasive approach in breast cancer therapy using magnetic resonance imaging-guided focused ultrasound surgery.
Cancer research 2001;61(23):8441-7.
2001: Gunter von Minckwitz; Günther Raab; Martin Schütte; Jörn Hilfrich; Jens-Uwe Blohmer; Bernd Gerber; Serban-Dan Costa; Elisabeth Merkle; Holger Eidtmann; Dieter Lampe; Christian Jackisch; Andreas du Bois; Augustinus-Harjanto Tulusan; Günther Gademann; Hans-Peter Sinn; Angelika Caputo; Erika Graf; Manfred Kaufmann
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Zentralblatt für Gynäkologie 2001;123(9):497-504.
2001: MA Weigand; Gernot Hartung; J Roboz; Stephanie Sieger; M Wolf; Hans-Peter Sinn; Hans-Hermann Schrenk; Manfred Wiessler; Eva Frei
Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone.
Anti-cancer drug design 2001;16(4-5):227-37.
2001: A Seute; Hans-Peter Sinn; Richard F Schlenk; Robert Emig; Diethelm Wallwiener; Eva-Maria Grischke; Stefan Hohaus; Hartmut Döhner; Rainer Haas; Martin Bentz
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients.
International journal of cancer. Journal international du cancer 2001;93(1):80-4.
2001: Angelika Burger; Gernot Hartung; Gerd Stehle; Hans-Peter Sinn; Heinz-Herbert Fiebig
Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo.
International journal of cancer. Journal international du cancer 2001;92(5):718-24.
2001: Tobias Schilling; J Bürck; Hans-Peter Sinn; A Clemens; Herwart F Otto; Wolfgang Höppner; Christian Herfarth; Reinhard Ziegler; M Schwab; Friedhelm Raue
Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.
International journal of cancer. Journal international du cancer 2001;95(1):62-6.
2001: Hans-Peter Sinn; A Magener; F Dürr; A Harcos; G von Minckwitz
[Predictive and prognostic factors in breast cancer evaluated by immunohistological methods].
Verhandlungen der Deutschen Gesellschaft für Pathologie 2001;85():200-5.
2001: Tobias Reuther; Alexander C Kübler; Uwe Zillmann; Christa Flechtenmacher; Hans-Peter Sinn
Comparison of the in vivo efficiency of photofrin II-, mTHPC-, mTHPC-PEG- and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma.
Lasers in surgery and medicine 2001;29(4):314-22.
2000: Paul Kremer; Andreas Wunder; Hans-Peter Sinn; Thomas Haase; Markus Rheinwald; Uwe Zillmann; FK Albert; Stefan Kunze
Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results.
Neurological research 2000;22(5):481-9.
2000: Ute Hamann; Hans-Peter Sinn
Survival and tumor characteristics of German hereditary breast cancer patients.
Breast cancer research and treatment 2000;59(2):185-92.
2000: Consolato Sergi; A Magener; Volker Ehemann; E M De Villiers; Hans-Peter Sinn
Stage IIa cervix carcinoma with metastasis to the heart: report of a case with immunohistochemistry, flow cytometry, and virology findings.
Gynecologic oncology 2000;76(1):133-8.
1999: Gerd Stehle; Andreas Wunder; Hans-Hermann Schrenk; Gernot Hartung; DL Heene; Hans-Peter Sinn
Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
Anti-cancer drugs 1999;10(8):785-90.
1999: Michael V Knopp; E Weiss; Hans-Peter Sinn; J Mattern; H Junkermann; J Radeleff; A Magener; Gunnar Brix; Stefan Delorme; Ivan Zuna; Gerhard van Kaick
Pathophysiologic basis of contrast enhancement in breast tumors.
Journal of magnetic resonance imaging : JMRI 1999;10(3):260-6.
1999: Gerd Stehle; Andreas Wunder; Hans-Hermann Schrenk; Gernot Hartung; DL Heene; Hans-Peter Sinn
Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats.
Anti-cancer drugs 1999;10(4):405-11.
1999: Gernot Hartung; Gerd Stehle; Hans-Peter Sinn; Andreas Wunder; Hans-Hermann Schrenk; Steffen Heeger; M Kränzle; Lutz Edler; E Frei; H H Fiebig; DL Heene; W Maier-Borst; Wolfgang Queisser
Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):753-9.
1998: Gerd Stehle; Andreas Wunder; Gernot Hartung; Hans-Peter Sinn
Albumin synthesis rates in cachectic cancer patients with an ongoing acute-phase protein response.
Annals of surgery 1998;228(5):720.
1998: Andreas Wunder; Gerd Stehle; Hans-Hermann Schrenk; Gernot Hartung; DL Heene; W Maier-Borst; Hans-Peter Sinn
Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.
International journal of cancer. Journal international du cancer 1998;76(6):884-90.
1998: Hans-Peter Sinn; HW Anton; A Magener; Dietrich Von Fournier; Gunther Bastert; Herwart F Otto
Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy.
European journal of cancer (Oxford, England : 1990) 1998;34(5):646-53.
1998: Erich Solomayer; Ingo J Diel; Gabriele C Meyberg; Hans-Peter Sinn; Robert Emig; Diethelm Wallwiener; Gunther Bastert
[Complete remission after salvage chemotherapy in metastatic breast carcinoma after failure of induction cycles of planned high dosage chemotherapy with stem cell support].
Zentralblatt für Gynäkologie 1998;120(7):337-40.
1997: Gerd Stehle; Andreas Wunder; Hans-Peter Sinn; Hans-Hermann Schrenk; S Schütt; Eva Frei; Gernot Hartung; W Maier-Borst; DL Heene
Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.
Anti-cancer drugs 1997;8(9):835-44.
1997: Gerd Stehle; Hans-Peter Sinn; Andreas Wunder; Hans-Hermann Schrenk; S Schütt; W Maier-Borst; DL Heene
The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.
Anti-cancer drugs 1997;8(7):677-85.
1997: Gerd Stehle; Hans-Peter Sinn; Andreas Wunder; Hans-Hermann Schrenk; J C Stewart; Gernot Hartung; W Maier-Borst; DL Heene
Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia.
Critical reviews in oncology/hematology 1997;26(2):77-100.
1997: Hans-Peter Sinn; N M Kellerhoff; R Kellerhoff; Gunther Bastert; Herwart F Otto
[Subtyping and prognostic assessment of invasive lobular breast carcinoma].
Der Pathologe 1997;18(1):37-44.
1997: Hans-Peter Sinn; D Haag; Volker Ehemann; A Magener; K Goerttler; Gunther Bastert; Herwart F Otto
[DNA cytometry in breast carcinoma. Review of method and value in assessing prognosis].
Der Pathologe 1997;18(1):19-26.
1997: Gerd Stehle; Andreas Wunder; Hans-Peter Sinn; Hans-Hermann Schrenk; Job Harenberg; Reinhard Malsch; W Maier-Borst; DL Heene
Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the rat.
Seminars in thrombosis and hemostasis 1997;23(1):31-7.
1996: H Junkermann; H Schmid; Hans-Peter Sinn; D Wallwiener
[Response evaluation with mammography and ultrasound].
Zentralblatt für Gynäkologie 1996;118(10):572-3.
1995: John H Clorius; Hans-Peter Sinn; H G Manke; Hans-Hermann Schrenk; J Blatter; C Werling; E A Friedrich; Jürgen Voges; Malte L Bahner; Volker Sturm
Serum albumin (SA) accumulation by bronchogenic tumours: a tracer technique may help with patient selection for SA-delivered chemotherapy.
European journal of nuclear medicine 1995;22(9):989-96.
1995: Manfred Kaufmann; K H Heider; Hans-Peter Sinn; Gunter von Minckwitz; Helmut Ponta; Peter Herrlich
CD44 isoforms in prognosis of breast cancer.
Lancet 1995;346(8973):502.
1995: Michael V Knopp; H Junkermann; Hans-Peter Sinn
[Monstrous breast tumor].
Der Radiologe 1995;35(5):363-6.
1995: Andreas Wunder; Gerd Stehle; Hans-Peter Sinn; Hans-Hermann Schrenk; B Neufeld; C E Dempfle; Hans Dresel; E Freidrich; Job Harenberg; W Maier-Borst
The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat.
Thrombosis research 1995;78(2):139-49.
1995: Manfred Kaufmann; K H Heider; Hans-Peter Sinn; Gunter von Minckwitz; Helmut Ponta; Peter Herrlich
CD44 variant exon epitopes in primary breast cancer and length of survival.
Lancet 1995;345(8950):615-9.
1995: Peter Dall; K H Heider; Hans-Peter Sinn; P Skroch-Angel; Günther R Adolf; Manfred Kaufmann; Peter Herrlich; Helmut Ponta
Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer.
International journal of cancer. Journal international du cancer 1995;60(4):471-7.
1995: Gerd Stehle; Andreas Wunder; Hans-Peter Sinn; Hans-Hermann Schrenk; E A Friedrich; C E Dempfle; W Maier-Borst; DL Heene
Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats.
The Journal of surgical research 1995;58(2):197-204.
1995: Hans-Peter Sinn; K H Heider; P Skroch-Angel; Gunter von Minckwitz; Manfred Kaufmann; Peter Herrlich; Helmut Ponta
Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44.
Breast cancer research and treatment 1995;36(3):307-313.
1994: Michael V Knopp; Gunnar Brix; H Junkermann; Hans-Peter Sinn
MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy.
Magnetic resonance imaging clinics of North America 1994;2(4):633-58.
1994: Hans-Peter Sinn; H Schmid; H Junkermann; J Huober; G Leppien; M Kaufmann; G Bastert; Herwart F Otto
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
Geburtshilfe und Frauenheilkunde 1994;54(10):552-8.
1994: Hans-Peter Sinn; A Oelmann; H W Anton; Ingo J Diel
Metastatic potential of small and minimally invasive breast carcinomas.
Virchows Archiv : an international journal of pathology 1994;425(3):237-41.
1993: Gerd Stehle; Hans-Peter Sinn; E A Friedrich; Andreas Wunder; Hans-Hermann Schrenk; Job Harenberg; Peter Peschke; C E Dempfle; W Maier-Borst; DL Heene
Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats.
The Journal of laboratory and clinical medicine 1993;122(6):728-38.
1992: Gerd Stehle; E A Friedrich; Hans-Peter Sinn; Andreas Wunder; Job Harenberg; C E Dempfle; W Maier-Borst; DL Heene
Hepatic uptake of a modified low molecular weight heparin in rats.
The Journal of clinical investigation 1992;90(5):2110-6.
1992: U Schilling; E A Friedrich; Hans-Peter Sinn; Hans-Hermann Schrenk; John H Clorius; W Maier-Borst
Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1992;19(6):685-95.
1992: E Ottnad; D P Via; J Frübis; Hans-Peter Sinn; E Friedrich; Reinhard Ziegler; Hans Dresel
Differentiation of binding sites on reconstituted hepatic scavenger receptors using oxidized low-density lipoprotein.
The Biochemical journal 1992;281 ( Pt 3)():745-51.
1992: Hans-Peter Deigner; E Friedrich; Hans-Peter Sinn; Hans Dresel
Scavenging of lipid peroxidation products from oxidizing LDL by albumin alters the plasma half-life of a fraction of oxidized LDL particles.
Free radical research communications 1992;16(4):239-46.
1990: E Ottnad; D P Via; Hans-Peter Sinn; E Friedrich; Reinhard Ziegler; Hans Dresel
Binding characteristics of reduced hepatic receptors for acetylated low-density lipoprotein and maleylated bovine serum albumin.
The Biochemical journal 1990;265(3):689-98.
1990: S Matzku; H Krempel; H P Weckenmann; Volker Schirrmacher; Hans-Peter Sinn; H Stricker
Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases.
Cancer immunology, immunotherapy : CII 1990;31(5):285-91.
1990: Hans-Peter Sinn; Hans-Hermann Schrenk; E A Friedrich; U Schilling; W Maier-Borst
Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1990;17(8):819-27.
1989: Hans-Peter Sinn; C Kandetzki; T Lehnert; R Waldherr
[Immunohistochemical classification of stromal tumors of the stomach].
Der Pathologe 1989;10(4):244-51.
1989: WH Knapp; J Debatin; F Helus; Hans-Peter Sinn; H Ostertag
Increased thermal response to ultrasound in the Walker carcinosarcoma treated with vasoactive drugs.
Cancer research 1989;49(7):1768-72.
1989: H P Weckenmann; S Matzku; H Stricker; Hans-Peter Sinn
Stability in biological fluids and clearance of immunoliposomes.
Arzneimittel-Forschung 1989;39(3):415-20.
1988: E Ottnad; D P Via; Hans-Peter Sinn; E Friedrich; Reinhard Ziegler; Hans Dresel
Evidence in liver for a disulphide-linked scavenger receptor containing a binding site for acetylated low-density lipoprotein and maleylated bovine serum albumin.
The Biochemical journal 1988;253(3):835-8.
1988: Hans-Peter Sinn; Hans-Hermann Schrenk; E A Friedrich; D P Via; Hans Dresel
Radioiodination of proteins and lipoproteins using N-bromosuccinimide as oxidizing agent.
Analytical biochemistry 1988;170(1):186-92.
1988: WH Knapp; M Panzer; F Helus; K Layer; Hans-Peter Sinn; H Ostertag
Effect of methotrexate on perfusion and nitrogen-13 glutamate uptake in the Walker-256 carcinosarcoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1988;29(2):208-16.
1988: Hans Dresel; E Otnad; E Friedrich; Hans-Peter Sinn; G Schettler; Reinhard Ziegler
Interaction of acetyl-LDL and Mal-BSA with scavenger receptor sites of rat liver.
Agents and actions. Supplements 1988;26():159-63.
1987: Hans Dresel; E Friedrich; D P Via; Hans-Peter Sinn; R Ziegler; G Schettler
Binding of acetylated low density lipoprotein and maleylated bovine serum albumin to the rat liver: one or two receptors?
The EMBO journal 1987;6(2):319-26.
1985: WH Knapp; J Debatin; K Layer; F Helus; A Altmann; Hans-Peter Sinn; H Ostertag
Selective drug-induced reduction of blood flow in tumor transplants.
International journal of radiation oncology, biology, physics 1985;11(7):1357-66.
1985: E Friedrich; Hans Dresel; Hans-Peter Sinn; G Schettler
Visualization of the hepatic low-density lipoprotein receptor in rats by sequential scintiscans.
FEBS letters 1985;184(1):134-8.
1985: Hans Dresel; E Friedrich; D P Via; G Schettler; Hans-Peter Sinn
Characterization of binding sites for acetylated low density lipoprotein in the rat liver in vivo and in vitro.
The EMBO journal 1985;4(5):1157-62.
1985: WH Knapp; F Helus; Franz Oberdorfer; K Layer; Hans-Peter Sinn; H Ostertag; S Matzku
11C-butanol for imaging of the blood-flow distribution in tumor-bearing animals.
European journal of nuclear medicine 1985;10(11-12):540-8.
1984: WH Knapp; F Helus; Hans-Peter Sinn; H Ostertag; P Georgi; W E Brandeis; A Braun
N-13 L-glutamate uptake in malignancy: its relationship to blood flow.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1984;25(9):989-97.
1980: P Georgi; L Strauss; Volker Sturm; H Ostertag; Hans-Peter Sinn; T Rommel
[Pre and intraoperative volume determination of craniopharyngioma cysts (author's transl)].
Nuklearmedizin. Nuclear medicine 1980;19(4):187-90.